
### [NCIT:C9154](http://purl.obolibrary.org/obo/NCIT_C9154)
**Label:** Adult Acute Myeloid Leukemia

**Subclasses:** [NCIT:C7319](http://purl.obolibrary.org/obo/NCIT_C7319) (Adult Acute Monoblastic and Monocytic Leukemia), [NCIT:C7964](http://purl.obolibrary.org/obo/NCIT_C7964) (Adult Acute Basophilic Leukemia), [NCIT:C7965](http://purl.obolibrary.org/obo/NCIT_C7965) (Adult Acute Megakaryoblastic Leukemia), [NCIT:C7882](http://purl.obolibrary.org/obo/NCIT_C7882) (Recurrent Adult Acute Myeloid Leukemia), [NCIT:C8303](http://purl.obolibrary.org/obo/NCIT_C8303) (Adult Acute Myeloid Leukemia with Minimal Differentiation), [NCIT:C7962](http://purl.obolibrary.org/obo/NCIT_C7962) (Adult Acute Myelomonocytic Leukemia), [NCIT:C7961](http://purl.obolibrary.org/obo/NCIT_C7961) (Adult Acute Myeloid Leukemia with Maturation), [NCIT:C9156](http://purl.obolibrary.org/obo/NCIT_C9156) (Adult Acute Monoblastic Leukemia), [NCIT:C8263](http://purl.obolibrary.org/obo/NCIT_C8263) (Adult Acute Monocytic Leukemia), [NCIT:C9155](http://purl.obolibrary.org/obo/NCIT_C9155) (Adult Acute Promyelocytic Leukemia with PML-RARA), [NCIT:C9153](http://purl.obolibrary.org/obo/NCIT_C9153) (Adult Acute Erythroid Leukemia), [NCIT:C68700](http://purl.obolibrary.org/obo/NCIT_C68700) (Adult Acute Myeloid Leukemia with Recurrent Genetic Abnormalities), [NCIT:C68698](http://purl.obolibrary.org/obo/NCIT_C68698) (Adult Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11), [NCIT:C9380](http://purl.obolibrary.org/obo/NCIT_C9380) (Adult Acute Myeloid Leukemia without Maturation), [NCIT:C68699](http://purl.obolibrary.org/obo/NCIT_C68699) (Adult Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1), [NCIT:C68696](http://purl.obolibrary.org/obo/NCIT_C68696) (Adult Acute Myeloid Leukemia with t(9;11)(p22.3;q23.3); MLLT3-KMT2A), [NCIT:C68697](http://purl.obolibrary.org/obo/NCIT_C68697) (Adult Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11), 

**Class expressions from DL-Learner:**

- Thing 53.00%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39957](http://purl.obolibrary.org/obo/NCIT_C39957) (Epididymal Adenocarcinoma))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39956](http://purl.obolibrary.org/obo/NCIT_C39956) (Rete Testis Adenoma))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 38.93%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 38.93%


